Solstice Neuro Nets $85 Million
Monday, November 27, 2006 7:30:00 AM PDT | VentureDeal Staff

MALVERN, PASolstice Neurosciences announced the closing of a new round of financing totaling $85 million of both equity and debt.

Highland Capital Management led the Series B round, with participation from earlier investors Thomas, McNerney & Partners, Investor Growth Capital Inc., Morgan Stanley Venture Partners, and Oxford Bioscience Partners.

The proceeds will allow the company to pursue continued development for treatments for movement disorders and cervical dystonia.